Anti-TNF Therapy Not Linked to Increased Malignancy Rate in Children with Juvenile Idiopathic Arthritis

Share this content:

(ChemotherapyAdvisor) – Children with juvenile idiopathic arthritis (JIA) have an increased rate of incident malignancy compared to children without JIA, which does not appear to be linked to treatment with TNF inhibitors, a study published in Arthritis & Rheumatism online February 10 has found.

The authors used U.S. Medicaid physician diagnosis codes and dispensed-medication prescription data from 2000–2005 to identify cohorts of 7,812 children with JIA and 321,821 children without JIA. Those with JIA represented 12,614 person-years of follow-up, and 1,484 children contributed 2,922 person-years of TNF inhibitor exposure.

For children with (vs. without) JIA, standardized incidence ratio was 4.4 (1.8–9.0) for probable and highly probable malignancies; for methotrexate users without TNF inhibitor use, SIR was 3.9 (0.4–14). No probable or highly probable malignancies were identified (SIR 0 (0–9.7)) following any use of TNF inhibitors.

The authors noted that in 2009, the FDA issued a warning about the possible association between TNF inhibitors and cancer risk in children; however, the analyses did not account for methotrexate exposure “or possible carcinogenic effects of the JIA disease process itself.” These data suggest risk from use of anti-TNF agents for JIA may be smaller than initially believed.

Abstract

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs